AUTHOR=Mahmoodi Ardalan , Shoqafi Ahmed , Sun Ping , Giannakeas Vasily , Cybulski Cezary , Nofech-Mozes Sharon , Masson Jean-Yves , Sharma Sudha , Samani Amir Abbas , Madhusudan Srinivasan , Narod Steven A. , Akbari Mohammad R. 

TITLE=High Expression of RECQL Protein in ER-Positive Breast Tumours Is Associated With a Better Survival

JOURNAL=Frontiers in Oncology

VOLUME=Volume 12 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.877617

DOI=10.3389/fonc.2022.877617

ISSN=2234-943X

ABSTRACT=Background: RECQL (also known as RECQ1 and RECQL1) is a gene of recent interest in breast cancer and an association between high levels of RECQL protein in breast cancer tumour cells and good survival of patients has been reported. 
Methods: To validate this association, we measured the RECQL protein levels in tumours of 933 breast cancer patients using immunohistochemistry analysis and followed the patients for death from breast cancer. 
Results: Women with a level of RECQL protein above the 75th percentile had better 15-year disease-specific survival among ER-positive patients (62.5% vs. 48.7%, HR= 0.72, 95%CI= 0.52-0.98, p-value = 0.04), but not among ER- patients (48.9% vs. 48.0%, HR= 1.07, 95%CI= 0.67-1.69, p-value= 0.79).  Among the ER-positive patients, high RECQL protein levels were associated with better survival among women who received tamoxifen treatment (67.0% vs. 51.5%, HR= 0.64, 95%CI= 0.41-0.99, p-value= 0.04). 
Conclusion: RECQL might be a new predictive marker for tamoxifen treatment among ER-positive patients.